Pamela Trillo

Medical Oncologist @IEOufficiale University of Milan @Lastatale
Thoracic oncologist #Lung cancer
#ArtificialIntelligence (AI) & #MachineLearning (ML) newbie

[Pamela Trillo @PamelaTrillo]

Happy to share our systematic review and meta-analysis published on #CTR. We investigated the predictive role of MGMT in patients with NETs treated with TEM-based chemotherapy.
@IEOufficiale @LaStatale @net_connectinfo
https://t.co/Mgrt1O6XQ5

[MV Chandrakanth @ChandrakanthMv]

WCLC 2026 | What am I watching? 🫁

Three spaces. 15 readouts worth watching.

🔹 Early NSCLC — Can we push more patients toward cure?
🔹 Advanced NSCLC — HER2, EGFR, ROS1 and ADC + IO reshape the first-line space.
🔹 SCLC — PCI, B7-H3 ADCs and DLL3: several long-standing questions may get new answers.

Some studies may reinforce practice.
Some may challenge it.
And some have already surprised us.

Seoul | 12–15 September 2026

Saving WCLC 2026 watchlist here 👇

#MVOnco #WCLC26 #IASLC #LungCancer #NSCLC #SCLC #ThoracicOncology #MedicalOncology

[Tom Newsom-Davis @tnewsomdavis]

PAPILLON: final OS
Chemo+Ami 1L EGFR Ex20 Ins

❗️76% X-over
✅mOS 34 v 27m, HR 0.87
✅X-over adjusted OS HR 0.57

🤔
Active, perhaps best OS data of 3 options (sunvo, zipa, ami) so far
Adjusted OS data exploratory IMO
Ami = challenging skin AEs

#WCLC26

[Pamela Trillo @PamelaTrillo]

@CCortiMD @IEOufficiale @IstTumori @nig_onco @Fond_IEOMONZINO @LaStatale @FondazioneBona1 @curijoey @CarmenCriscit @stolaney1 @DFCI_BreastOnc @paomanca @IdaTaglialatel1 @jacopo_uli @fedgiugliano @margheambro1 @CateSposetti @CriminiMd @AgostaraAlberto Congratulazioni! 🎊😃

[Jarushka Naidoo @DrJNaidoo]

Interesting multi-omic analysis of previously classified SCLC cell lines (YAP1+), identifies that these tumors represent diseases that ‘mimic’ SCLC- in this case- SMARCA4-deficient thoracic tumors, that have a poor prognosis

@CCR_AACR @OncoAlert #LCSM

https://t.co/dOuxMzjU1P

[Journal for ImmunoTherapy of Cancer @jitcancer]

New #JITC position article and guidelines: Corticosteroid-resistant immune-related adverse events: a systematic review https://t.co/kCXMkFCF0W @LImmunotherapy @AlfredZippelius @cappelliMD @DrJNaidoo

[NEJM @NEJM]

In the TRIDENT-1 phase 1–2 trial, the TK inhibitor repotrectinib led to an objective response in 79% of patients with ROS1 fusion–positive NSCLC and no previous ROS1 TK inhibitor use. Median progression-free survival was nearly 3 years. Full trial results: https://t.co/Yp96EdePOl

[ESMO - Eur. Oncology @myESMO]

#ESMO23: Over 3,400 slides, webcasts, abstracts & ePosters are now available on OncologyPRO 👉 practice-changing data and state-of-the-art educational content from more than 20 tracks.
https://t.co/IWaIxFImRi

#MedTwitter #OncTwitter

[Pamela Trillo @PamelaTrillo]

We met a "big star" in the session poster at @Esmo2023. @bensolomon1

[Pamela Trillo @PamelaTrillo]

My #Esmo2023
Madrid- Spain

[ESMO - Eur. Oncology @myESMO]

#ESMO23: That exciting time of the year 🙌Almost all late-breaking abstract titles and authors are now online. Head to the programme and check out all the impressive science you can look forward to. This year we received 4,565 abstracts, an increase of +30% (YOY). See you in Madrid or online! Registration: https://t.co/nu0ITF97vT
@AndresC27622123 @Silke_Gillessen @DrAngelaLamarca @fdinicolantonio @lillian_siu @LizzySmyth1 @ChiaraCrem1 @TeresaSAmaral @marinagarassino @JMMartinMoreno @SilviaStacchia @TanjaSpanic @DrJonLim

[Oncology Brothers @OncBrothers]

#WCLC23 Highlights #CommunityOncology 🔎:

1. #IMPower133 update ES-SCLC @StephenVLiu

2. #DESTINYLung02 Her2 NSCLC

3. #MARS2: ✂️mesothelioma @ekslim

4. #FLAURA2: 1L mEGFR

5. 2L mEGFR: #CHRYSALIS2 #HERTHENALung01

6. TNM 9thEd

#lcsm @IASLC #OncTwitter #MedTwitter #MedEd

[Benjamin Besse @BenjaminBesseMD]

Flaura-2: escalation from osi to osi + CT makes sense in pts with ‘hard to treat’ EGFRmut NSCLC: exon 21, brain mets, and probably if symptoms/high tumor burden since PS1 pts derive more benefit than PS0. ~5X more Gr3 AEs & no signal in OS: not obvious in all comers. #WCLC2023

[Rami Manochakian MD, FASCO @RManochakian]

🔥🚨@OncoAlert Hot off the press, presented @IASLC #WCLC23, results of
#HERTHENA-Lung01 trial of
#Patritumab Deruxtecan (HER3-DXd) in #EGFR-Mutated #NSCLC Following EGFR TKI & Chemo.

ORR: 30% mDOR: 6.4 months
DCR: 74%
iORR: 33%
mPFS: 5.5 months
mOS: 11.9 months

Safety profile consistent with prior reports.

[Jorge Alatorre Alexander @JorgeAlatorreA1]

FLAURA2 dem that combination of osi + Chemo is better than chemo alone and tolerable!! Amazing results for our EGFR pts!!#WCLC2023 @IASLC PFS 29.9 vs 19.9 mo by BICR. Exon 19 (27.9 mo ) & L858R (24.7 mo). Practice changing!! Congrat to the researchers!!

[Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ @APassaroMD]

🚨PressRelease by ⁦@JanssenGlobal⁩

The combo of amivantamab plus p-based chemo (w/ or w/out Lazertinib) vs chemo alone achieved a statistically significant & clinically meaningful improvement in PFS in NSCLC with EGFR mut’s after Osimertinib https://t.co/UyMy2PYdSa

[Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ @APassaroMD]

☄️#PressRelease
The combination of Osimertinib plus chemo showed a strong PFS improvement vs Osi alone for patients with EGFR-mutated advanced lung cancer in FLAURA2 Ph III trial #LCSM

📌2023 will be an historical year for EGFR+ management: stay tuned 🔊
https://t.co/ulRJLY97UV

[Dr. Antonio Calles 🫁🚭 @Tony_Calles]

Good news for patients with potentially resectable NSCLC. 3-year analysis from CM-816 neoadjuvant Nivo + Chemo shows long-term EFS benefit vs chemo and preliminary promising OS. Nicely presented by @nicogirardcurie #ELCC23 #LCSM

[Clinical Lung Cancer @ClinicalLung]

Just published @ClinicalLung!

In a prospective study of 207 patients with thoracic cancer receiving anticancer treatment (including immunotherapy), COVID-19 mRNA vaccines appeared to be safe without new safety concerns.

Learn more: https://t.co/1y00qvnIE8

[Julien Mazieres @JulienMazieres]

Update of KN-407. With ~5 years follow-up, pembro (vs placebo) + chemo maintained an OS + PFS benefit in advanced sq #NSCLC regardless of PD-L1. 20% of patients alive / half without tumor recurrence after 5 yrs. Still need improvement but it's impressive. #ESMO22 @OncoAlert

[Julien Mazieres @JulienMazieres]

⚠️First results of INSIGHT-2 trial #ESMO22. Combo of tepotinib and osimertinib is feasible and associated with 54.5% ORR (in FISH + TBx patients) in METamp patients displaying progression under 1L osimertinib. @OncoAlert